AU2002328921B2 - Combinations comprising epothilones and pharmaceutical uses thereof - Google Patents

Combinations comprising epothilones and pharmaceutical uses thereof Download PDF

Info

Publication number
AU2002328921B2
AU2002328921B2 AU2002328921A AU2002328921A AU2002328921B2 AU 2002328921 B2 AU2002328921 B2 AU 2002328921B2 AU 2002328921 A AU2002328921 A AU 2002328921A AU 2002328921 A AU2002328921 A AU 2002328921A AU 2002328921 B2 AU2002328921 B2 AU 2002328921B2
Authority
AU
Australia
Prior art keywords
acid
treatment
combination
lower alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002328921A
Other languages
English (en)
Other versions
AU2002328921A1 (en
Inventor
Tianling Chen
Diane Greeley
John David Rothermel
Markus Wartmann
Jeanette Marjorie Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002328921A1 publication Critical patent/AU2002328921A1/en
Priority to AU2005246964A priority Critical patent/AU2005246964B2/en
Application granted granted Critical
Publication of AU2002328921B2 publication Critical patent/AU2002328921B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002328921A 2001-07-19 2002-07-18 Combinations comprising epothilones and pharmaceutical uses thereof Ceased AU2002328921B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2005246964A AU2005246964B2 (en) 2001-07-19 2005-12-20 Combinations comprising epothilones and pharmaceutical uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30655901P 2001-07-19 2001-07-19
US30657101P 2001-07-19 2001-07-19
US30656001P 2001-07-19 2001-07-19
US60/306,559 2001-07-19
US60/306,560 2001-07-19
US60/306,571 2001-07-19
PCT/EP2002/008020 WO2003007924A2 (en) 2001-07-19 2002-07-18 Combinations comprising epothilones and pharmaceutical uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005246964A Division AU2005246964B2 (en) 2001-07-19 2005-12-20 Combinations comprising epothilones and pharmaceutical uses thereof

Publications (2)

Publication Number Publication Date
AU2002328921A1 AU2002328921A1 (en) 2003-05-22
AU2002328921B2 true AU2002328921B2 (en) 2006-11-02

Family

ID=27405180

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002328921A Ceased AU2002328921B2 (en) 2001-07-19 2002-07-18 Combinations comprising epothilones and pharmaceutical uses thereof
AU2005246964A Ceased AU2005246964B2 (en) 2001-07-19 2005-12-20 Combinations comprising epothilones and pharmaceutical uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2005246964A Ceased AU2005246964B2 (en) 2001-07-19 2005-12-20 Combinations comprising epothilones and pharmaceutical uses thereof

Country Status (19)

Country Link
US (3) US20040235796A1 (enExample)
EP (2) EP2210643A3 (enExample)
JP (2) JP2005501825A (enExample)
KR (2) KR20040030808A (enExample)
CN (2) CN101791308A (enExample)
AU (2) AU2002328921B2 (enExample)
BR (1) BR0211271A (enExample)
CA (1) CA2453108A1 (enExample)
CO (1) CO5560565A2 (enExample)
EC (2) ECSP084948A (enExample)
HU (1) HUP0401153A3 (enExample)
IL (2) IL159517A0 (enExample)
MX (1) MXPA04000567A (enExample)
NO (1) NO20040214L (enExample)
NZ (2) NZ550174A (enExample)
PL (1) PL365030A1 (enExample)
RU (1) RU2375058C2 (enExample)
TW (1) TWI315982B (enExample)
WO (1) WO2003007924A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE554756T1 (de) 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
SI1686997T1 (sl) 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
CN103638028A (zh) 2005-05-02 2014-03-19 诺瓦提斯公司 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
CN100384419C (zh) * 2005-12-02 2008-04-30 菏泽睿鹰制药集团有限公司 一种埃坡霉素缓释植入组合物及应用
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
RU2478407C1 (ru) * 2011-09-05 2013-04-10 Федеральное государственное бюджетное учреждение Министерства здравоохранения и социального развития Российской Федерации "Медицинский радиологический научный центр" (ФГБУ МРНЦ Минздравсоцразвития России) Способ комбинированного лечения местно-распространенного рака желудка

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039694A2 (en) * 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
FR2775187A1 (fr) * 1998-02-25 1999-08-27 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
WO2000018439A2 (de) * 1998-09-29 2000-04-06 Schering Aktiengesellschaft Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
WO2000049019A2 (de) * 1999-02-18 2000-08-24 Schering Aktiengesellschaft Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) * 1946-10-22 Method for obtaining hydantoins
US3475486A (en) * 1966-09-12 1969-10-28 Monsanto Co Process for preparing phosphonic acids
FR2182943A1 (en) 1972-04-10 1973-12-14 Rustenburg Platinum Mines Ltd Cis-dihalo-bis(ethyleneimine) platinum (ii) derivs - anti-cancer agents
CH605550A5 (enExample) 1972-06-08 1978-09-29 Research Corp
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
FR2694558B1 (fr) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
EP0675723A4 (en) 1992-12-23 1998-08-05 Merck & Co Inc THERAPY USING BISPHOSPHONATES AND STROGENS TO TREAT AND PREVENT BONE RESORPTION.
AU2989695A (en) 1994-08-08 2000-03-07 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation
WO1996039149A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE59609305D1 (de) * 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
ATE267197T1 (de) 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
EP1579871A1 (en) 1998-12-22 2005-09-28 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
RU2236251C2 (ru) 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
ATE329596T1 (de) 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
GB9907908D0 (en) * 1999-04-07 1999-06-02 Bataille Regis Organic compounds
EP1178810B8 (en) * 1999-05-21 2005-07-27 Novartis AG Use of bisphosphonic acids for treating angiogenesis
JP2003519183A (ja) * 2000-01-04 2003-06-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心臓および動脈の石灰化を抑制する低用量ビスホスホネートの使用
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
WO2001058899A1 (en) 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
ATE554756T1 (de) 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039694A2 (en) * 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
FR2775187A1 (fr) * 1998-02-25 1999-08-27 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
WO2000018439A2 (de) * 1998-09-29 2000-04-06 Schering Aktiengesellschaft Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
WO2000049019A2 (de) * 1999-02-18 2000-08-24 Schering Aktiengesellschaft Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung

Also Published As

Publication number Publication date
RU2375058C2 (ru) 2009-12-10
CN101791308A (zh) 2010-08-04
CA2453108A1 (en) 2003-01-30
RU2004105144A (ru) 2005-04-20
JP2005501825A (ja) 2005-01-20
EP2210643A2 (en) 2010-07-28
ECSP094948A (es) 2009-12-28
IL159517A0 (en) 2004-06-01
KR20090040925A (ko) 2009-04-27
HUP0401153A3 (en) 2008-01-28
JP2010159271A (ja) 2010-07-22
MXPA04000567A (es) 2004-04-20
NZ550174A (en) 2008-04-30
US20040235796A1 (en) 2004-11-25
US7612052B2 (en) 2009-11-03
EP2210643A3 (en) 2010-11-24
HUP0401153A2 (hu) 2004-10-28
US8008330B2 (en) 2011-08-30
NZ530572A (en) 2006-11-30
IL159517A (en) 2012-04-30
WO2003007924A2 (en) 2003-01-30
US20090318390A1 (en) 2009-12-24
BR0211271A (pt) 2004-08-03
KR20040030808A (ko) 2004-04-09
EP1412029A2 (en) 2004-04-28
PL365030A1 (en) 2004-12-27
TWI315982B (en) 2009-10-21
CO5560565A2 (es) 2005-09-30
AU2005246964B2 (en) 2008-04-24
AU2005246964A1 (en) 2006-01-12
US20080119529A1 (en) 2008-05-22
CN1533293A (zh) 2004-09-29
CN1283248C (zh) 2006-11-08
WO2003007924A3 (en) 2003-09-25
NO20040214L (no) 2004-03-18
ECSP084948A (es) 2008-08-29

Similar Documents

Publication Publication Date Title
US8008330B2 (en) Combinations comprising epothilones and pharmaceutical uses thereof
US20040034026A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
ZA200307665B (en) Combination comprising N-{5-[4-(4-methyl-piperazinomethyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and a chemotherapeutic agent.
AU2002328921A1 (en) Combinations comprising epothilones and pharmaceutical uses thereof
EP1819331B1 (en) Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof
US20050033034A1 (en) Anti-t cell immunotoxin fusion protein and its therapeutic use
AU2008203233B2 (en) Combinations comprising epothilones and pharmaceutical uses thereof
ZA200309898B (en) Combinations comprising epothilones and pharmaceutical use thereof.
AU2003223958B2 (en) Combinations comprising epothilone derivatives and alkylating agents
EP1545534B1 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
US7754716B2 (en) Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor
CN101669958A (zh) 二膦酸类化合物的药物应用
MXPA06006278A (en) Pharmaceutical uses of bisphosphonates
CN1911218A (zh) 包含埃坡霉素的组合及其药学应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired